PRESS RELEASE published on 11/12/2024 at 08:30, 9 days 4 hours ago Predilife lance une émission d'obligations de 2M EUR à un taux de 8,5% par an sur 5 ans
BRIEF published on 11/07/2024 at 18:35, 13 days 18 hours ago Subsidiary of MammoRisk by Predilife for €202 million MammoRisk Breast Cancer International Development Subsidiary Valorization
BRIEF published on 11/07/2024 at 18:35, 13 days 18 hours ago Filialisation de MammoRisk par Predilife pour 202 M€ Développement International Valorisation MammoRisk Cancer Du Sein Filialisation
PRESS RELEASE published on 11/07/2024 at 18:30, 13 days 18 hours ago Réalisation de l'apport partiel d'actif de MammoRisk à une valorisation de 202 M EUR Predilife annonce la réalisation de l'apport partiel d'actif de MammoRisk à une valorisation de 202 M€ pour favoriser son développement international. Création de valeur et partenariats en vue Développement International Valorisation PREDILIFE MammoRisk Apport Partiel D'actif
BRIEF published on 10/30/2024 at 19:05, 21 days 17 hours ago Predilife publishes its 2024 half-yearly financial report Artificial Intelligence Financial Report Euronext Growth PREDILIFE Medical Prediction
BRIEF published on 10/30/2024 at 19:05, 21 days 17 hours ago Predilife publie son rapport financier semestriel 2024 Euronext Growth Rapport Financier Intelligence Artificielle PREDILIFE Prédiction Médicale
PRESS RELEASE published on 10/30/2024 at 19:00, 21 days 17 hours ago Predilife met à disposition son rapport financier semestriel 2024 Predilife met à disposition son rapport financier semestriel 2024, spécialiste des solutions de prédiction de pathologies pour une médecine personnalisée Rapport Financier Médecine Personnalisée PREDILIFE Pathologies Prédiction
BRIEF published on 10/28/2024 at 08:35, 24 days 4 hours ago PREDILIFE Half-Yearly Results and Outlook for 2024 Financial Results Strategic Partnerships Growth 2024 PREDILIFE MammoRisk®
BRIEF published on 10/28/2024 at 08:35, 24 days 4 hours ago Résultats Semestriels et Perspectives de PREDILIFE pour 2024 Résultats Financiers Partenariats Stratégiques Croissance 2024 PREDILIFE MammoRisk®
PRESS RELEASE published on 10/28/2024 at 08:30, 24 days 4 hours ago Résultats semestriels 2024 - Perspectives de croissance 2024 Annonce des résultats semestriels 2024 et perspectives de croissance pour PREDILIFE, spécialiste des solutions de prédiction de risques de pathologies. Des partenariats stratégiques et une croissance attendue Croissance Résultats Semestriels Partenariats Stratégiques PREDILIFE Bilans Prédictifs
Published on 11/21/2024 at 12:00, 38 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 38 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 8 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 35 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 38 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:15, 23 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 8 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 37 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 06:58, 5 hours 40 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 40 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 40 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 31 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 18 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
